European guideline and expert statements on the management of narcolepsy in adults and children
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
European guideline and expert statements on the management of narcolepsy in adults and children. / Bassetti, Claudio L. A.; Kallweit, Ulf; Vignatelli, Luca; Plazzi, Giuseppe; Lecendreux, Michel; Baldin, Elisa; Dolenc-Groselj, Leja; Jennum, Poul; Khatami, Ramin; Manconi, Mauro; Mayer, Geert; Partinen, Markku; Pollmaecher, Thomas; Reading, Paul; Santamaria, Joan; Sonka, Karel; Dauvilliers, Yves; Lammers, Gert J.
I: European Journal of Neurology, Bind 28, Nr. 9, 2021, s. 2815-2830.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - European guideline and expert statements on the management of narcolepsy in adults and children
AU - Bassetti, Claudio L. A.
AU - Kallweit, Ulf
AU - Vignatelli, Luca
AU - Plazzi, Giuseppe
AU - Lecendreux, Michel
AU - Baldin, Elisa
AU - Dolenc-Groselj, Leja
AU - Jennum, Poul
AU - Khatami, Ramin
AU - Manconi, Mauro
AU - Mayer, Geert
AU - Partinen, Markku
AU - Pollmaecher, Thomas
AU - Reading, Paul
AU - Santamaria, Joan
AU - Sonka, Karel
AU - Dauvilliers, Yves
AU - Lammers, Gert J.
PY - 2021
Y1 - 2021
N2 - Background and purpose Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children. Methods The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach. Results A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions. Conclusion The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.
AB - Background and purpose Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children. Methods The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach. Results A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions. Conclusion The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.
KW - cataplexy
KW - European
KW - guideline
KW - management
KW - narcolepsy
KW - EXCESSIVE DAYTIME SLEEPINESS
KW - QUALITY-OF-LIFE
KW - ADMINISTERED SODIUM OXYBATE
KW - ONSET CHILDHOOD NARCOLEPSY
KW - GAMMA-HYDROXYBUTYRATE GHB
KW - STEVENS-JOHNSON SYNDROME
KW - PERIODIC LEG MOVEMENTS
KW - ORAL JZP-110 ADX-N05
KW - LONG-TERM USE
KW - DOUBLE-BLIND
U2 - 10.1111/ene.14888
DO - 10.1111/ene.14888
M3 - Journal article
C2 - 34173695
VL - 28
SP - 2815
EP - 2830
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 9
ER -
ID: 286856573